HDAC9 and cancer: In the current study, we observed metabolic reprogramming in HDAC inhibitor-induced, quiescent CSC-like cells that contrasts with that of the un-induced, differentiated cancer cells, with activation of the glycolytic pathway accompanied by high PPP activity, as indicated by high glucose consumption, high NADPH production, and high G6PD expression.